We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.
- Authors
Krop, Ian; Demuth, Tim; Guthrie, Tina; Wen, Patrick Y; Mason, Warren P; Chinnaiyan, Prakash; Butowski, Nicholas; Groves, Morris D; Kesari, Santosh; Freedman, Steven J; Blackman, Samuel; Watters, James; Loboda, Andrey; Podtelezhnikov, Alexei; Lunceford, Jared; Chen, Cong; Giannotti, Maxine; Hing, Jeremy; Beckman, Robert; Lorusso, Patricia
- Abstract
Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor of γ-secretase, an enzyme required for Notch pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of MK-0752.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 19, p2307
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.39.1540